Operator
Welcome to Tivic’s Conference Call to Discuss Fiscal Year and Fourth Quarter 2025 Financial Results. This call has been prerecorded. This call is being webcast, and the replay will be available on the IR section of the company’s website for 3 months.
Before we begin, please note that during today’s call, management will make various forward-looking statements. Investors are cautioned that these forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated in our forward-looking statements. Please read the safe harbor statement contained in the press release that Tivic Health issued today as well as the risk factors contained in Tivic Health’s filings with the SEC, including its annual report on Form 10-K for the year-end December 31, 2025, which is expected to be filed with the SEC on March 31, 2026, as well as other companies’ SEC filings.
On today’s call, we have Tivic Health’s Chief Executive Officer, Michael Handley; and Chief Financial Officer, Lisa Wolf.
Now let me turn the call over to Michael.
Michael Handley
CEO & Director
Thank you, and welcome, everybody. It is a privilege to address you for the first time as CEO of Tivic. I’m honored to lead the company at this transformative juncture. My focus is clear and resolute evolving Tivic into a high-impact immunotherapy company dedicated to saving lives, advancing critical therapies to patients and delivering significant long-term value to our shareholders.
This year, 2025 was a defining year and a year of strategic transformation. We completed a fundamental pivot